Mizuho raises Sage Therapeutics target to $9 on Biogen bid
Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...
Sage Group’s Strong Financial Performance and Positive Growth Outlook in 2025
In a report released today, Charles Brennan from Jefferies maintained a Buy rating on Sage Group plc (SGE – Research Report), with a price ...
Pharmaceutical Technology2d
Sage rejects Biogen’s $469m takeover bid
Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...